Published in AIDS Weekly, January 8th, 2001
A total of 200 patients with AIDS-related Kaposi's sarcoma are being sought to participate in a multi-national, Phase III, randomized, placebo-controlled, double-blinded study of IM862, a drug developed by Cytran, Inc. of Kirkland, Washington.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.